Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.

Ann Med · 2023 · PMC9848335 · PMID 36644935

Europe PMC DOI

hedged sentence

0.0774

closest p · 1.5× alpha

0.0774

boldest claim

The sentences

showed a trendp = .0774so close (0.05 < p ≤ 0.1)

Similarly, patients treated with HMAs plus ruxolitinib showed a trend towards longer survival than HMAs alone [one-year OS rate: 25% (95%CI: 16–36%; I 2 =68.2%) and 11% (95% CI: 3–24%; I 2 =31.8%) respectively, p = .0774; two-year OS rate: 33% (95% CI: 15–54%; I 2 =34.8%) and 3% (95% CI: 0–18%; I 2 =65.2%), p = .051; Figure 4(c,d) ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.